March 6, 2018 9:00am

CLBS closed at $5.03 and is up +$1.58 or +31.41% - BUY


CLBS acquired from Shire plc (SHP.L) (SHPG) an exclusive worldwide license to data from a late stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina. 

  • Under the terms of the agreement, CLBS acquired rights to the data set and regulatory filings for the CD34+ cell therapy program for the treatment of refractory angina.  In exchange, Shire will receive undisclosed up-front consideration, milestones and a royalty on product sales.    


  • The comprehensive data set that Caladrius licensed includes preclinical (in vivo and in vitro) and P1, P2 and P3 clinical study data of CD34 cell therapy as a treatment for no-option refractory angina, along with the corresponding regulatory filings. 


About Refractory Angina: It is estimated that as many as one million people in the United States have chronic symptomatic coronary artery disease (often referred to as refractory angina) that is recalcitrant to medical therapy and unamenable to conventional revascularization procedures. Patients have reproducible lifestyle-limiting symptoms of chest pain, shortness of breath, and easy fatigability. These symptoms are often due to totally occluded coronary arteries or diffuse coronary atherosclerosis that makes revascularization problematic. As the population ages and the incidence of diabetes mellitus increases, this clinical condition will become more prevalent. Patients with this condition have significant morbidity and experience a lower quality of life.